184 related articles for article (PubMed ID: 35840339)
1. Disease activity of lung cancer at the time of acute exacerbation of interstitial lung disease during cytotoxic chemotherapy.
Sekine A; Matama G; Hagiwara E; Tabata E; Ikeda S; Oda T; Okuda R; Kitamura H; Baba T; Satoh H; Misumi T; Komatsu S; Iwasawa T; Ogura T
Thorac Cancer; 2022 Sep; 13(17):2443-2449. PubMed ID: 35840339
[TBL] [Abstract][Full Text] [Related]
2. The ATS/ERS/JRS/ALAT statement "IPF by HRCT" could predict acute exacerbation of interstitial lung disease in non-small cell lung cancer.
Asai N; Katsuda E; Hamanaka R; Kosaka K; Matsubara A; Nishimura M; Tanaka H; Yokoe N; Takahashi A; Yamaguchi E; Kubo A
Tumori; 2017 Jan; 103(1):60-65. PubMed ID: 27791236
[TBL] [Abstract][Full Text] [Related]
3. Low forced vital capacity predicts cytotoxic chemotherapy-associated acute exacerbation of interstitial lung disease in patients with lung cancer.
Enomoto Y; Inui N; Kato T; Baba T; Karayama M; Nakamura Y; Ogura T; Suda T
Lung Cancer; 2016 Jun; 96():63-7. PubMed ID: 27133752
[TBL] [Abstract][Full Text] [Related]
4. The risk of cytotoxic chemotherapy-related exacerbation of interstitial lung disease with lung cancer.
Kenmotsu H; Naito T; Kimura M; Ono A; Shukuya T; Nakamura Y; Tsuya A; Kaira K; Murakami H; Takahashi T; Endo M; Yamamoto N
J Thorac Oncol; 2011 Jul; 6(7):1242-6. PubMed ID: 21623239
[TBL] [Abstract][Full Text] [Related]
5. Glasgow prognostic score for prediction of chemotherapy-triggered acute exacerbation interstitial lung disease in patients with small cell lung cancer.
Kikuchi R; Takoi H; Tsuji T; Nagatomo Y; Tanaka A; Kinoshita H; Ono M; Ishiwari M; Toriyama K; Kono Y; Togashi Y; Yamaguchi K; Yoshimura A; Abe S
Thorac Cancer; 2021 Jun; 12(11):1681-1689. PubMed ID: 33939332
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy-associated Acute Exacerbation of Interstitial Lung Disease Shortens Survival Especially in Small Cell Lung Cancer.
Nakao S; Yamaguchi K; Sakamoto S; Horimasu Y; Masuda T; Miyamoto S; Nakashima T; Iwamoto H; Fujitaka K; Hamada H; Hattori N
Anticancer Res; 2019 Oct; 39(10):5725-5731. PubMed ID: 31570474
[TBL] [Abstract][Full Text] [Related]
7. Protective effect of bevacizumab on chemotherapy-related acute exacerbation of interstitial lung disease in patients with advanced non-squamous non-small cell lung cancer.
Hamada S; Ichiyasu H; Ikeda T; Inaba M; Kashiwabara K; Sadamatsu T; Sato N; Akaike K; Okabayashi H; Saruwatari K; Tomita Y; Saeki S; Hirata N; Yoshinaga T; Fujii K
BMC Pulm Med; 2019 Apr; 19(1):72. PubMed ID: 30940113
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of second-line chemotherapy for patients with advanced non-small cell lung cancer complicated by interstitial lung disease.
Otsuka K; Nokihara H; Mitsuhashi A; Ozaki R; Yabuki Y; Yoneda H; Ogino H; Nishioka Y
Thorac Cancer; 2022 Nov; 13(21):2978-2984. PubMed ID: 36106507
[TBL] [Abstract][Full Text] [Related]
9. The extent of ground-glass attenuation is a risk factor of chemotherapy-related exacerbation of interstitial lung disease in patients with non-small cell lung cancer.
Masuda T; Hirano C; Horimasu Y; Nakashima T; Miyamoto S; Iwamoto H; Ohshimo S; Fujitaka K; Hamada H; Hattori N
Cancer Chemother Pharmacol; 2018 Jan; 81(1):131-139. PubMed ID: 29143072
[TBL] [Abstract][Full Text] [Related]
10. Glasgow Prognostic Score predicts chemotherapy-triggered acute exacerbation-interstitial lung disease in patients with non-small cell lung cancer.
Kikuchi R; Takoi H; Tsuji T; Nagatomo Y; Tanaka A; Kinoshita H; Ono M; Ishiwari M; Toriyama K; Kono Y; Togashi Y; Yamaguchi K; Yoshimura A; Abe S
Thorac Cancer; 2021 Mar; 12(5):667-675. PubMed ID: 33480111
[TBL] [Abstract][Full Text] [Related]
11. Acute exacerbation of rheumatoid arthritis-associated interstitial lung disease: clinical features and prognosis.
Izuka S; Yamashita H; Iba A; Takahashi Y; Kaneko H
Rheumatology (Oxford); 2021 May; 60(5):2348-2354. PubMed ID: 33241299
[TBL] [Abstract][Full Text] [Related]
12. The utility of ground-glass attenuation score for anticancer treatment-related acute exacerbation of interstitial lung disease among lung cancer patients with interstitial lung disease.
Nishiyama N; Honda T; Sema M; Kawahara T; Jin Y; Natsume I; Chiaki T; Yamashita T; Tsukada Y; Taki R; Miyashita Y; Saito K; Tateishi T; Sakashita H; Miyazaki Y
Int J Clin Oncol; 2020 Feb; 25(2):282-291. PubMed ID: 31720993
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of
Akaike K; Saruwatari K; Oda S; Shiraishi S; Takahashi H; Hamada S; Iyama S; Horio Y; Tomita Y; Saeki S; Okamoto S; Ichiyasu H; Fujii K; Sakagami T
Int J Clin Oncol; 2020 Apr; 25(4):681-690. PubMed ID: 31781994
[TBL] [Abstract][Full Text] [Related]
14. Impact of Interstitial Lung Disease Classification on the Development of Acute Exacerbation of Interstitial Lung Disease and Prognosis in Patients with Stage III Non-Small-Cell Lung Cancer and Interstitial Lung Disease Treated With Chemoradiotherapy.
Kobayashi H; Naito T; Omae K; Omori S; Nakashima K; Wakuda K; Ono A; Kenmotsu H; Murakami H; Endo M; Harada H; Takahashi T
J Cancer; 2018; 9(11):2054-2060. PubMed ID: 29896291
[No Abstract] [Full Text] [Related]
15. Analysis of acute exacerbation of interstitial lung disease associated with chemotherapy in patients with lung cancer: A feasibility of S-1.
Kakiuchi S; Hanibuchi M; Tezuka T; Saijo A; Otsuka K; Sakaguchi S; Toyoda Y; Goto H; Kawano H; Azuma M; Ogushi F; Nishioka Y
Respir Investig; 2017 Mar; 55(2):145-152. PubMed ID: 28274530
[TBL] [Abstract][Full Text] [Related]
16. Nationwide survey of radiation therapy in Japan for lung cancer complicated with interstitial lung disease.
Hagiwara Y; Nakayama Y; Kudo S; Hayakawa T; Nakamura N; Kitamoto Y; Takahashi S; Tsujino K; Kubo N; Tamaki Y; Nagata Y;
J Radiat Res; 2020 Jul; 61(4):563-574. PubMed ID: 32363376
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the safety and efficacy of combination chemotherapy with vinorelbine and platinum agents for patients with non-small cell lung cancer with interstitial lung disease.
Okuda K; Hirose T; Oki Y; Murata Y; Kusumoto S; Sugiyama T; Ishida H; Shirai T; Nakashima M; Yamaoka T; Ohnishi T; Ohmori T
Anticancer Res; 2012 Dec; 32(12):5475-80. PubMed ID: 23225454
[TBL] [Abstract][Full Text] [Related]
18. Association of the RAGE/RAGE-ligand axis with interstitial lung disease and its acute exacerbation.
Yamaguchi K; Iwamoto H; Sakamoto S; Horimasu Y; Masuda T; Miyamoto S; Nakashima T; Fujitaka K; Hamada H; Hattori N
Respir Investig; 2022 Jul; 60(4):531-542. PubMed ID: 35504814
[TBL] [Abstract][Full Text] [Related]
19. The role of interleukin-6 as a prognostic biomarker for predicting acute exacerbation in interstitial lung diseases.
Lee JH; Jang JH; Park JH; Jang HJ; Park CS; Lee S; Kim SH; Kim JY; Kim HK
PLoS One; 2021; 16(7):e0255365. PubMed ID: 34314462
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy for patients with advanced lung cancer with interstitial lung disease: a prospective observational study.
Koda K; Enomoto Y; Aoshima Y; Amano Y; Kato S; Hasegawa H; Matsui T; Yokomura K; Mochizuki E; Matsuura S; Koshimizu N; Morita M; Kojima S; Watanabe A; Oyama Y; Ikeda M; Kusagaya H; Uto T; Sato J; Imokawa S; Kono M; Hashimoto D; Kamiya Y; Toyoshima M; Asada K; Morita M; Mikamo M; Yasui H; Hozumi H; Karayama M; Suzuki Y; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Inui N; Suda T
Ther Adv Chronic Dis; 2022; 13():20406223221108395. PubMed ID: 35782342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
